Weisman Harlan F's Form 4 filing
TFF Pharmaceuticals, Inc. (TFFP) · filed Mar 13, 2023
- Accession no.
- 0001213900-23-019384
- Filed
- Mar 13, 2023
- Trade date
- Mar 10, 2023
- Filing delay
- 3 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 1 non-derivative transaction. Open-market purchases total $132.0K. It was filed 3 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Weisman Harlan FCIK 0001555563 | Director, Officer (President and CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 10, 2023 | Common Stock | PPurchaseAcquired | +150,000 | $0.88F1 | +$132,000 | 214,615 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The reported shares were purchased in the open market in one transaction at the price of $0.8789.
Referenced by the price of 1 transaction in Table I.